Condition
Multiple Myeloma Clinical Trials
Studies of multiple myeloma, matched by condition name and medical subject headings. Start with those open to enrolment.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 704Multiple Myeloma, Exercise
Prehab Prior to Stem Cell Transplantation in Multiple Myeloma
The primary purpose of this study is to see if individuals with Multiple Myeloma are able and interested in taking part in a tailored exercise program while undergoing their chemotherapy prior to a stem cell transplant.
- Conditions
- Multiple Myeloma, Exercise, Prehabilitation
- Trial name
- MOTIVATE (NCT06280924)
- Testing
- Supported Exercise, Standard Care
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of Alberta
Multiple Myeloma, Plasma Cell Leukemia
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Historically, the frailest patients with multiple myeloma are under-represented in clinical trials, and have very high rates of treatment discontinuation, and early treatment mortality.
- Trial name
- UltraFrailMM (NCT06517017)
- Testing
- Isatuximab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Utah
Malignancy, Hematologic, Neoplasms, Hematologic
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes.
- Conditions
- Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer
- Trial name
- NCT06904066
- Testing
- aldesleukin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
This phase II trial compares the effect of the combination of daratumumab-hyaluronidase (daratumumab) and teclistamab to the usual treatment of daratumumab, pomalidomide, dexamethasone or daratumumab, carfilzomib and…
- Trial name
- NCT06948084
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib
- Where
- 29 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression
Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study
Treatment for blood cancers has improved significantly, and more patients are now living longer. However, these treatments are often intensive and long-lasting, and many patients experience serious side effects and symptoms.
- Conditions
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression, Multiple Myeloma Refractory
- Trial name
- NCT07634263
- Where
- 3 sites in Denmark
- Volunteers
- 50 people
- Sponsor
- Odense University Hospital
Multiple Myeloma (MM), CART Therapy
Neurocognitive Trajectories After BCMA CAR-T
The purpose of this research study is to evaluate cognitive changes over time in participants with relapsed or refractory multiple myeloma who have received chimeric antigen receptor T-cell therapy (CAR-T).
- Conditions
- Multiple Myeloma (MM), CART Therapy, Refractory Multiple Myeloma (RRMM)
- Trial name
- CAR-T Cog (NCT07740317)
- Testing
- Standardized neurocognitive testing
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wake Forest University Health Sciences
Myeloma Multiple
RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of Elranatamab
Elranatamab is an effective BCMA-targeting bispecific antibody for relapsed/refractory multiple myeloma (RRMM). However, implementation in routine practice remains challenging due to monitoring requirements during step-up dosing…
- Trial name
- RE-RITE (NCT07891871)
- Volunteers
- 400 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Newly Diagnosed Multiple Myeloma (NDMM)
Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma
The goal of this clinical trial is to evaluate whether a modified (less frequent) dosing schedule of daratumumab, when added to standard VRd therapy, can be an effective induction regimen for treating newly diagnosed multiple…
- Trial name
- NCT07891923
- Testing
- Daratumumab (Intravenously) with VRd (Bortezomib, Lenalidomide, and Dexamethasone)
- Where
- 2 sites in India
- Volunteers
- 52 people
- Sponsor
- Tata Memorial Centre
Lyphoma, B-Cell, Leukemia, B-cell
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Background: Gene therapy is a way to treat or prevent disease using genes. It is monitored very closely by regulators because there can be long-term, unexpected side effects.
- Conditions
- Lyphoma, B-Cell, Leukemia, B-cell, Multiple Myeloma, Hematologic Malignancies
- Trial name
- NCT02473757
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Myeloma
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36…
- Conditions
- Multiple Myeloma, Myeloma, Myeloma Multiple
- Trial name
- NCT05651932
- Testing
- Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)
- Where
- 29 sites in United States, Canada and 2 more
- Volunteers
- 165 people
- Sponsor
- K36 Therapeutics, Inc.
Completed, with results posted
All –Multiple Myeloma
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma.
- Trial name
- NCT04649359
- Testing
- Elranatamab (PF-06863135)
- Where
- 78 sites in United States, Australia and 8 more
- Volunteers
- 187 people
- Sponsor
- Pfizer
Cancer Prevention, Weight Loss
PROFAST Intervention in Precursor Multiple Myeloma
This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM)…
- Conditions
- Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS
- Trial name
- PROFAST (NCT05565638)
- Testing
- Prolonged Fasting Intervention, EDUCATION CONTROL
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
The purpose of this study is to evaluate the safety and effectiveness of an investigational new drug called carfilzomib, in combination with dexamethasone in subjects with newly diagnosed multiple myeloma followed by treatment…
- Trial name
- CarBiRD (NCT01559935)
- Testing
- carfilzomib, Dexamethasone, Clarithromycin
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Weill Medical College of Cornell University
Elranatamab, Myeloma
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
The purpose of this study is to understand the study medicine (called Elranatamab, or PF-06863135) as potential treatment for refractory multiple myeloma.
- Conditions
- Elranatamab, Myeloma, Multiple Myeloma, Relapsed Multiple Myeloma
- Trial name
- NCT05228470
- Testing
- Elranatamab
- Where
- 15 sites in China
- Volunteers
- 39 people
- Sponsor
- Pfizer
Multiple Myeloma
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to see whether pomalidomide (also known as Pomalyst) reduces the number of myeloma cells in the bones, and to see what is the best way to use pomalidomide in patients with myeloma.
- Trial name
- NCT01745588
- Testing
- Pomalidomide, stem cell, Dexamethasone
- Where
- 10 sites in United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center